Ali BORAZAN, Doğan BİNİCİ NASIR, YASİN ÖZTÜRK

Periton diyalizi hastalarında NCEP-ATP III ve IDF’ye göre metabolik sendrom sıklığı

Amaç: Bu çalışmada periton diyalizi uygulanan hastalarda Ulusal Kolesterol Eğitim Programı Erişkin Tedavi Paneli III (NCEP-ATP III) ve Uluslararası Diyabet Federasyonu (IDF) tarafından tanımlanan metabolik sendrom sıklığını karşılaştırmayı amaçladık. Yöntem: Bu çalışmaya periton diyalizi yapılan toplam 74 hasta alındı. Yaş, cinsiyet, ağırlık, bel çevresi, arteriyel kan basınçları, açlık kan şekeri, total kolesterol, LDL-kolesterol, HDLkolesterol, trigliserid ölçümleri dosya kayıtlarından alındı. Her iki yönteme göre de metabolik sendrom tanısı alanlarla almayanlar arasında yaş, ağırlık, bel çevresi, total kolesterol, LDL-kolesterol, HDL-kolesterol, trigliserid ortalamaları yönünden farklılıklar student-t test ile, cinsiyet, hipertansiyon ve diyabetes mellitus oranları yönünden farklılıklar ise χ2 testi ile analiz edildi. Bulgular: Hastalarda hem NCEP-ATP III hem de IDF kriterlerine göre değerlendirildiğinde 19 (% 25,7) hastada metabolik sendrom varlığı tespit edildi. Metabolik sendrom sıklığı NCEPATPIII tanı kriterleri ile tanısı % 52,7 oranında tespit edilirken IDF tanı kriterleri kullanıldığında % 32,4 hastada metabolik sendrom tespit edildi. Sonuç: Periton diyalizi hastalarında metabolik sendrom oranının yüksek olması nedeniyle bu hastalarda hem tanı esnasında hem de daha sonra düzenli aralıklarla metabolik sendrom açısından da değerlendirilmesinin uygun olacağını düşünmekteyiz.

Frequency of metabolic syndrome among peritoneal dialysis patients according to NCEP-ATP III and IDF definitions

Objective: In the present study, it was aimed to evaluate the frequency of metabolic syndrome using the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) definitions in patients with peritoneal dialysis. Methods: A total of 74 cases undergoing peritoneal dialysis patients were enrolled in the study. Age, sex, weight, waist circumference, arterial blood pressure, fasting blood glucose, serum total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides were recorded. The differences between these methods in diagnosing student’s t-test was used to compare age, weight, waist circumference, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides levels, while χ2 test was used to compare gender, hypertension, and diabetes mellitus between MS-diagnosed and undiagnosed patients in both methods. Results: Both NCEP-ATP III and IDF definitions, the diagnosis of metabolic syndrome was 25.7% respectively. The ratio of metabolic syndrome diagnoses was higher for NCEP-ATP III 52.7% compared to IDF definitions 32.4% respectively. Conclusion: It is logical to evaluate patients with for metabolic syndrome at the time of diagnosis and regularly thereafter due to the high ratio of metabolic syndrome in peritoneal dialysis patients.

PDF

___

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998:32;853–906.
2. Genestier S, Hedelin G, Schaffer P, Faller B: Prognostic factors in CAPD patients: A retrospective study of a 10-year period. Nephrol Dial Transplant 1995;10:1905–11.
3. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003;27:1283–9.
4. Zimmet P, Boyko EJ, Collier GR, De Courten M. Etiology of the metabolic syndrome: potential role of insulin resistence, leptin resistance, and other players. Ann NY Acad Sci 1999;892:25-44.
5. Nieuwdorp M, Stroes ES, Meijers JC, Büller H. Hypercoagulability in the metabolic syndrom. Current Opin Pharmacol 2005;5:155–9.
6. World Health Organization Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. WHO: Geneva, Switzerland; 1999.
7. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486– 97.
8. The IDF consensus worldwide definition of the metabolic syndrome. Vol 2005, International Diabetes Federation 2005.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998;15:539–53.
10. American Diabetes Association diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27:S5-S10.
11. Grundy SM. Metabolic syndrome pandemic Arterioscler Thromb Vasc Biol 2008;28:629–36.
12. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005;81:543–54.
13. Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: Saint or sinner. Perit Dial Int 2005;25:415–25.
14. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, et al. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007;12:391–8.
15. Kayabaşı H, Yılmaz Z, Yıldırım İ, Yıldırım Y, Kadiroğlu AK, Yılmaz ME. Sürekli ayaktan periton diyalizi hastalarında metabolik sendrom sıklığı ve metabolik sendrom gelişiminin diyaliz süresi ile ilişkisi. Turk Neph Dial Transpl 2011;20:168–72.
16. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374–81.
17. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102: 42–7.
18. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953–66.
19. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999;22(suppl 3):10-3.
20. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without Creactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–9.
21. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 2003;26:557–62.
22. Liao CT, Kao TW, Chou YH, Wu MS, Chen YM, Chuang HF, et al. Associations of metabolic syndrome and its components with cardiovascular outcomes among nondiabetic patients undergoing maintenance peritoneal dialysis. Nephrol Dial Transplant 2011;26:4047-54.
23. Gören B, Fen T. Metabolik sendrom. Turkiye Klinikleri J Med Sci 2008;28: 686–96.